In Brief: Ciba Self-Medication
This article was originally published in The Tan Sheet
Ciba Self-Medication: Lisa Gonzalez named VP-marketing for Ciba Self-Medication and of Novartis Self-Medication pending regulatory approval of the Ciba/Sandoz merger, effective Sept. 23. Gonzalez currently is VP-Americas of Glaxo Wellcome's OTC Commercial Operations unit, with commercial oversight for all North American switches. Charlie Lay assumes management responsibility for Ciba's U.S. Pharmaceuticals Division following the departure of James Callahan, who had been tapped as Novartis U.S. CEO but opted to take early retirement "for personal and professional reasons," Ciba says. Sandoz Corp. CEO E.J. Fullagar has been given responsibility for the integration of the Ciba/Sandoz U.S. pharmaceutical business until a new CEO is found. The search firm Russell Reynolds has been hired to help find a replacement...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC